Vivos Therapeutics, Inc.

Health Care
Medical/Dental Instruments
www.vivos.com

Moat Score
Safety Score

Market Cap $17.86M
PE -1
Debt $1.20M
Cash $6.31M
EV $12.75M
FCF -$13.07M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$12.57M
EBIT	-$12.57M
ROE	-164%
ROA	-82%
FCF	-$13.07M
Equity	$7.67M
Growth Stability	1
PE	-1.42
PB	2.33
P/FCF	-1.37
P/S	1.22
Price/Cash	0.35
Debt/Equity	0.16
Debt/FCF	-0.09
Net Margins	-73%
Gross Margins	61%
Op. Margins	-86%
Sales Growth YoY	17%
Sales Growth QoQ	-5%
Sales CAGR	-1%
Equity CAGR	-62%
Earnings Growth YoY	25%

Earnings Growth QoQ	36%
Sales CAGR 5Y	-1%
Equity CAGR 5Y	-62%
Earnings CAGR 3Y	-8%
Sales CAGR 3Y	-8%
Equity CAGR 3Y	-66%
Market Cap	$17.86M
Revenue	$14.58M
Assets	$15.35M
Total Debt	$1.20M
Cash	$6.31M
Shares Outstanding	4.28M
EV	12.75M
Moat Score	1%
Safety Score	65%
Working Capital	2.27M
Current Ratio	1.44
Gross Profit	$8.86M
Shares Growth 3y	14%
Equity Growth QoQ	21%
Equity Growth YoY	17K%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (OSA). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have been used to treat over 15,000 patients worldwide by more than 1,100 trained dentists.

SEC Filings

Direct access to Vivos Therapeutics, Inc. (VVOS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Vivos Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Vivos Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Vivos Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Vivos Therapeutics, Inc..

Years

Calculation mode

= -$131M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$13M	-$13M	-$13M	-$13M	-$13M	-$13M	-$13M	-$13M	-$13M	-$13M	-$13M	-$131M
DCF		-$12M	-$11M	-$9.8M	-$8.9M	-$8.1M	-$7.4M	-$6.7M	-$6.1M	-$5.5M	-$5M	-$50M
Value	-$131M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-103%	-138%	-120%	-149%	-98%	-73%
ROA	-	-48%	-60%	-174%	-127%	-82%
ROE	-	-106%	-79%	-497%	-3K%	-164%

Bad Net Margins (-73.32%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.37	-0.14	-	-0.09	-0.09
Debt over Equity	-2.52	0.13	0.1	-	2.92	0.16
Growth Stability	-	-	-	-	-	1

Good Debt/FCF ratio (-0.09)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.16)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	15%	29%	-5%	-14%	-1%
Earnings YoY growth	-	53%	13%	18%	-43%	-
Equity YoY growth	-	-675%	51%	-81%	-91%	-62%
FCF YoY growth	-	5%	213%	13%	-38%	-